ICER slightly softens its recommendation on Pfizer’s ATTR-CM drug price

A US drug pricing watchdog has raised the range by which it thinks Pfizer’s heart muscle disease drug tafamidis, marketed as Vyndamax and Vyndaqel, should …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

resolves on cash capital increase under exclusion of subscription rights in the amount of up to 10% of the share capital, commitments from investors – Biotech Investments

Vita 34 AG / Key word(s): Capital Increase Vita 34 AG: resolves on cash capital increase under exclusion of subscription rights in the amount of

November 28, 2023

Rentschler Biopharma announces largest single investment at its headquarters in Germany – Biotech Investments

EQS-News: Rentschler Biopharma SE / Key word(s): Strategic Company Decision/Expansion Rentschler Biopharma announces largest single investment at its headquarters in Germany 24.10.2024 / 07:30 CET/CEST

October 25, 2024

Compound Management and its Crucial Role in Early Pharmaceutical Research

In this interview conducted at SLAS EU 2023 in Brussels, Belgium, we spoke to Silvio Di Castro about his research, as well as the role of

September 7, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.